Ignite Creation Date:
2024-05-06 @ 8:26 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06383832
Status:
COMPLETED
Last Update Posted:
2024-04-25
First Post:
2024-03-13
Brief Title:
Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet
Sponsor:
Sun Jia
Organization:
Zhujiang Hospital
Study Overview
Official Title:
Effect of Dapagliflozin on Body Weight in Overweight Women Consuming Different Proportions of Carbohydrate Diet
Status:
COMPLETED
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In recent years the prevalence of overweight and obesity has increased dramatically worldwide of which 343 and 164 of adults in China are overweight and obese respectively ranking first in the worlds obese population Dapagliflozin is a sodium-glucose transporter 2 Inhibitors that inhibits glucose reabsorption and promotes urinary glucose excretion by inhibiting renal proximal tubular sodium-glucose transporter 2 Inhibitors for the treatment of type 2 diabetes mellitus The urinary glucose excretion induced by dapagliflozin can induce weight loss through energy loss or body water loss caused by osmotic diuresis In addition in patients with type 2 diabetes dapagliflozin may also induce weight loss by reducing body fat as well as subcutaneous and visceral fatIn a randomized controlled trial type 2 diabetes patients treated with sodium-glucose transporter 2 Inhibitors lost approximately 1-3 kg Also sodium-glucose transporter 2 Inhibitors have shown good weight loss in obese people without type 2 diabetes In real-world studies a minority of type 2 diabetes patients taking dapagliflozin experienced weight gain The American Lipid Association defines a low carbohydrate diet as the calorie intake of carbohydrates accounting for 10-25 of the total daily energy intake In a randomized controlled trial a low-carbon diet showed a more significant decrease in body weight fat mass index whole body fat and visceral fat after 8 weeks compared to the standard diet So this study intends to investigate whether the weight loss effect of dapagliflozin is affected by different dietary structures
Detailed Description:
Record the following indicators before and after intervention including height weight BMI blooAccording to previous literature dapagliflozin has a weight loss effect on overweightobese individuals This study is a prospective open label single arm exploratory clinical trial expected to include 36 overweight women The subjects enter a 4-week introduction period during which they need to maintain their original dietary habits and record a 24-hour dietary review on the 3rd of each week At the end of the introduction period if the weight change of the subject is less than 3 it is considered qualified Then qualified subjects will receive a 12 week intervention with dapagliflozin tablets oral 10mg once a day During the experiment participants were required to maintain their original dietary habits unchanged Participants are required to record their dietary habits for three days a week in order to determine their energy intake and carbohydrate energy ratio d pressure waist circumference abdominal circumference waist to hip ratio morning urine routine 24-hour urine glucose fasting blood glucose fasting insulin blood lipids TGTCLDLHDL body fat percentage body fat mass muscle mass subcutaneous fat visceral fat volume and abdominal fat volume and record any adverse reaction events that occurred during the study Collect patient urine and serum samples for testing Collect patient feces freeze the samples in a -80 freezer and send the feces to a biological company for testing of intestinal microbiota composition
Conduct subgroup analysis based on the 24-hour dietary review provided by the subjects on the 3rd day of the week during the introduction period subjects with carbohydrate energy greater than or equal to 26 of their daily energy intake will be included in the non low carbohydrate group NCD group and subjects with carbohydrate energy accounting for 10-25 of their daily energy intake will be included in the low carbohydrate group LCD group
Conduct subgroup analysis based on the 24-hour dietary review provided by the subjects on the 3rd day of the week during the introduction period subjects with carbohydrate energy greater than or equal to 26 of their daily energy intake will be included in the non low carbohydrate group NCD group and subjects with carbohydrate energy accounting for 10-25 of their daily energy intake will be included in the low carbohydrate group LCD group
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None